Wow, this company is worth ~AUD$16B, but it doesn't have any revenue or any approved drugs on the market (yet). It's drug for ALS failed, but their Ph 3 results for Aficamten for hypertrophic cardiomyopathy were very good and seems likely the drug will be approved.
Analyst https://seekingalpha.com/article/4591775-cytokinetics-temper-expectations-aficamten-crowded-hcm-market estimated the drug, if successful, could have peak sales of US$1.4 billion.
They apparently have several other trials in progress related to this.
Compares pretty favourably with Neuren in terms of stage and potential I'd have to say. Although Neuren's currently approved drug is tied up with Acadia they also arguably have greater market potential as well I'd say.
hottod likely will have a much better commentary to offer ;-)
Wow, this company is worth ~AUD$16B, but it doesn't have any...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $30.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.68 | 45 | 1 |
View Market Depth
| Last trade - 16.16pm 24/05/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable